Compare MELI & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MELI | GSK |
|---|---|---|
| Founded | 1999 | 1715 |
| Country | Uruguay | United Kingdom |
| Employees | N/A | 66841 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.0B | 108.7B |
| IPO Year | 2007 | N/A |
| Metric | MELI | GSK |
|---|---|---|
| Price | $1,815.38 | $52.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 2 |
| Target Price | ★ $2,666.47 | N/A |
| AVG Volume (30 Days) | 404.9K | ★ 4.3M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.40% |
| EPS Growth | ★ 4.54 | N/A |
| EPS | ★ 17.42 | N/A |
| Revenue | ★ $28,893,000,000.00 | N/A |
| Revenue This Year | $36.23 | $6.99 |
| Revenue Next Year | $24.20 | $4.19 |
| P/E Ratio | $105.22 | ★ $32.75 |
| Revenue Growth | ★ 39.06 | N/A |
| 52 Week Low | $1,495.00 | $37.71 |
| 52 Week High | $2,548.50 | $61.70 |
| Indicator | MELI | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 51.84 |
| Support Level | $1,754.59 | $49.92 |
| Resistance Level | $1,899.50 | $53.87 |
| Average True Range (ATR) | 46.83 | 1.06 |
| MACD | -2.16 | -0.00 |
| Stochastic Oscillator | 37.40 | 38.68 |
MercadoLibre is the largest e-commerce marketplace in Latin America, with more than 120 million unique active buyers and 1 million active sellers at the end of 2025. The company is roughly split between its e-commerce business, which includes its fulfillment and advertising services, and its fintech segment, which comprises its rapidly expanding payment and digital wallet platform (Mercado Pago) and its lending business (Mercado Credito). While the company operates in 18 countries, its primary markets are Brazil, Argentina, and Mexico, which account for more than 95% of its revenue.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.